249 related articles for article (PubMed ID: 18193917)
21. The effect of dietary protein on the clearance of allopurinol and oxypurinol.
Berlinger WG; Park GD; Spector R
N Engl J Med; 1985 Sep; 313(13):771-6. PubMed ID: 4033706
[TBL] [Abstract][Full Text] [Related]
22. The optimal use of allopurinol: an audit of allopurinol use in South Auckland.
Stamp L; Gow P; Sharples K; Raill B
Aust N Z J Med; 2000 Oct; 30(5):567-72. PubMed ID: 11108066
[TBL] [Abstract][Full Text] [Related]
23. Plasma concentrations and urinary excretion of purine bases (uric acid, hypoxanthine, and xanthine) and oxypurinol after rigorous exercise.
Kaya M; Moriwaki Y; Ka T; Inokuchi T; Yamamoto A; Takahashi S; Tsutsumi Z; Tsuzita J; Oku Y; Yamamoto T
Metabolism; 2006 Jan; 55(1):103-7. PubMed ID: 16324927
[TBL] [Abstract][Full Text] [Related]
24. Plasma oxipurinol concentrations during allopurinol therapy.
Emmerson BT; Gordon RB; Cross M; Thomson DB
Br J Rheumatol; 1987 Dec; 26(6):445-9. PubMed ID: 3690140
[TBL] [Abstract][Full Text] [Related]
25. The pharmacokinetics of injectable allopurinol in newborns with the hypoplastic left heart syndrome.
McGaurn SP; Davis LE; Krawczeniuk MM; Murphy JD; Jacobs ML; Norwood WI; Clancy RR
Pediatrics; 1994 Dec; 94(6 Pt 1):820-3. PubMed ID: 7970996
[TBL] [Abstract][Full Text] [Related]
26. The population pharmacokinetics of allopurinol and oxypurinol in patients with gout.
Wright DF; Stamp LK; Merriman TR; Barclay ML; Duffull SB; Holford NH
Eur J Clin Pharmacol; 2013 Jul; 69(7):1411-21. PubMed ID: 23475133
[TBL] [Abstract][Full Text] [Related]
27. Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol.
Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Hada T
J Rheumatol; 2001 Oct; 28(10):2294-7. PubMed ID: 11669172
[TBL] [Abstract][Full Text] [Related]
28. Determination of allopurinol and oxypurinol in human plasma and urine by liquid chromatography-tandem mass spectrometry.
Liu X; Ni XJ; Shang DW; Zhang M; Hu JQ; Qiu C; Luo FT; Wen YG
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Dec; 941():10-6. PubMed ID: 24184830
[TBL] [Abstract][Full Text] [Related]
29. Uric acid lowering effect of oxipurinol sodium in hyperuricemic patients - therapeutic equivalence to allopurinol.
Walter-Sack I; de Vries JX; Ernst B; Frei M; Kolb S; Kosmowski J; Priebe U; Schroder HE; Slotty C; Voss A; Weber A; Wegscheider K
J Rheumatol; 1996 Mar; 23(3):498-501. PubMed ID: 8832991
[TBL] [Abstract][Full Text] [Related]
30. Uricosuric medications for chronic gout.
Kydd AS; Seth R; Buchbinder R; Edwards CJ; Bombardier C
Cochrane Database Syst Rev; 2014 Nov; (11):CD010457. PubMed ID: 25392987
[TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects.
Graham S; Day RO; Wong H; McLachlan AJ; Bergendal L; Miners JO; Birkett DJ
Br J Clin Pharmacol; 1996 Apr; 41(4):299-304. PubMed ID: 8730975
[TBL] [Abstract][Full Text] [Related]
32. Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteers.
Ng DY; Stocker SL; Graham GG; Williams KM; Day RO
Eur J Clin Pharmacol; 2011 Jul; 67(7):709-13. PubMed ID: 21181139
[TBL] [Abstract][Full Text] [Related]
33. Bioequivalence of allopurinol-containing tablet preparations.
Barthel W; Hüller G; Haustein KO
Int J Clin Pharmacol Ther; 1999 Mar; 37(3):148-52. PubMed ID: 10190763
[TBL] [Abstract][Full Text] [Related]
34. [Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol].
Ohno I; Okabe H; Yamaguchi Y; Saikawa H; Uetake D; Hikita M; Gomi H; Ichida K; Hosoya T
Nihon Jinzo Gakkai Shi; 2008; 50(4):506-12. PubMed ID: 18546882
[TBL] [Abstract][Full Text] [Related]
35. Facile and rapid high-performance liquid chromatography method for simultaneous determination of allopurinol and oxypurinol in human serum.
Tada H; Fujisaki A; Itoh K; Suzuki T
J Clin Pharm Ther; 2003 Jun; 28(3):229-34. PubMed ID: 12795781
[TBL] [Abstract][Full Text] [Related]
36. Absorption and metabolism of allopurinol and oxypurinol by rat jejunum in vitro: effects on uric acid transport.
Shaw MI; Parsons DS
Clin Sci (Lond); 1984 Mar; 66(3):257-67. PubMed ID: 6692658
[TBL] [Abstract][Full Text] [Related]
37. Effects of angiotensin II infusion on renal excretion of purine bases and oxypurinol.
Moriwaki Y; Yamamoto T; Tsutsumi Z; Takahashi S; Hada T
Metabolism; 2002 Jul; 51(7):893-5. PubMed ID: 12077737
[TBL] [Abstract][Full Text] [Related]
38. Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open-label, drug-drug interaction study.
Tachibana M; Yamamura N; Atiee GJ; Hsu C; Warren V; He L; Dishy V; Zahir H
Br J Clin Pharmacol; 2018 Oct; 84(10):2317-2324. PubMed ID: 29920736
[TBL] [Abstract][Full Text] [Related]
39. Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion.
Day RO; Miners JO; Birkett DJ; Whitehead A; Naidoo D; Hayes J; Savdie E
Br J Clin Pharmacol; 1988 Oct; 26(4):423-8. PubMed ID: 3190992
[TBL] [Abstract][Full Text] [Related]
40. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
Reinders MK; Haagsma C; Jansen TL; van Roon EN; Delsing J; van de Laar MA; Brouwers JR
Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
